Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ProQR nets $54mm via FOPO

Executive Summary

ProQR Therapeutics NV (developing RNA therapies for severe genetic rare diseases) netted $54mm through the follow-on public offering of 10.45mm ordinary shares (including full exercise of the overallotment) at $5.50. The company will use the proceeds for ongoing pipeline development of its candidates including Phase II/III sepofarsen for Leber’s congenital amaurosis, Phase I/II QR421a for Usher syndrome Type 2, and Phase I/II-ready QR1123 for retinitis pigmentosa.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies